HCW Biologics, Inc. (HCWB)

In October 2025, the company presented preclinical data for its TRBC-Based T-Cell Engager Program and participated in the 2025 Maxim Growth Summit. In November 2025, HCW Biologics initiated a Phase 1 clinical trial to evaluate HCW9302 in patients with alopecia areata. In February 2026, the company announced the pricing of a $1.5 million follow-on offering of shares and warrants and entered into an agreement to reduce the exercise price of certain existing warrants. In March 2026, HCW Biologics regained compliance with all continued listing rules for Nasdaq. Also in March 2026, positive research results for HCW9206 were published in the journal Science Advances, and the company secured a $3.5 million upfront license fee (net $2.9 million). On March 26, 2026, HCW Biologics received a Nasdaq bid-price notice. On March 31, 2026, the company reported its fourth-quarter and fiscal year 2025 financial results, which included a significant revenue decline and disclosed substantial doubt about its ability to continue as a going concern. From April 8, 2025, to April 7, 2026, HCWB's share price experienced a substantial decline, and a 1-for-40 reverse stock split was effected on April 11, 2025.

There is no information available to indicate any specific demand seasonality for HCW Biologics Inc.'s products and services. Demand for its offerings is typically driven by research and development cycles, clinical trial progress, and the ongoing needs of the scientific and medical communities, rather than seasonal consumer patterns.

HCW Biologics Inc. is a clinical-stage biopharmaceutical company in the United States, focusing on novel immunotherapies to lengthen health span by disrupting the link between chronic inflammation and age-related diseases. The company utilizes the TOBI™ discovery platform and TRBC platform for designing immunotherapeutic drugs. Key product candidates include HCW9218, a clinical-stage bifunctional molecule that has completed Phase 1 for chemotherapy-refractory solid tumor cancers and Phase 1b/2 for pancreatic cancer, HCW9302, an injectable interleukin 2 (IL-2) fusion protein complex in Phase 1 for autoimmune and proinflammatory diseases, such as alopecia areata, HCW9201, a lead candidate designed to modulate the immune system and reduce chronic inflammation, HCW9206, a proprietary, commercial-ready cytokine-fusion scaffold, HCW11-006, an immune cell stimulator, HCW11-002 and HCW11-0027, immune checkpoint inhibitors for oncology and senescence-associated indications, and HCW11-018, fusions and immune cell engagers for cancer treatment. The company has also begun commercializing certain proprietary compounds as reagents for use in producing cell-based immunotherapeutics for infectious diseases and cancer.

HCW Biologics Inc. is headquartered in Miramar, Florida, United States, with operations primarily focused within the U.S.

The publication of positive preclinical data for its T-cell engager program and research results for HCW9206 in Science Advances, the initiation of a Phase 1 clinical trial for HCW9302, and regaining compliance with Nasdaq listing rules would enhance the company's scientific credibility. The significant decline in stock price, a substantial decrease in revenue, and the disclosure of substantial doubt about going concern would severely impact investor confidence and likely lead to a negative perception of the company's financial stability.

HCW Biologics Inc. has a notable institutional ownership presence, with 15 institutional owners and shareholders holding a total of 436,934 shares as of April 8, 2026. Major institutional owners include Armistice Capital, Llc, DRW Securities, LLC, Citadel Advisors Llc, Susquehanna International Group, Llp, Vanguard Group Inc, Geode Capital Management, Llc, J.w. Cole Advisors, Inc., Golden State Wealth Management, LLC, Tower Research Capital LLC (TRC), UBS Group AG, and Pullen Investment Management LLC. Individuals and insiders collectively hold 11.01% of the shares outstanding.